As ADAM10 and ADAM17 are overexpressed in glioblastoma where they can act to increase the EGF concentration in the niche then anti-ADAM10 and ADAM17 treatment may mediate migration out of the niche by reducing local EGF concentrations. Here, EGF is linked to glioblastoma.